Effect of beta‐blocker therapy on early mortality after emergency colonic cancer surgery.
Published: 27th September 2018
Authors: R. Ahl, P. Matthiessen, X. Fang, Y. Cao, G. Sjolin, R. Lindgren et al.
Emergency colorectal cancer surgery is associated with significant mortality. Induced adrenergic hyperactivity is thought to be an important contributor. Downregulating the effects of circulating catecholamines may reduce the risk of adverse outcomes. This study assessed whether regular preoperative beta‐blockade reduced mortality after emergency colonic cancer surgery.
This cohort study used the prospectively collected Swedish Colorectal Cancer Registry to recruit all adult patients requiring emergency colonic cancer surgery between 2011 and 2016. Patients were subdivided into those receiving regular beta‐blocker therapy before surgery and those who were not (control). Demographics and clinical outcomes were compared. Risk factors for 30‐day mortality were evaluated using Poisson regression analysis.
A total of 3187 patients were included, of whom 685 (21·5 per cent) used regular beta‐blocker therapy before surgery. The overall 30‐day mortality rate was significantly reduced in the beta‐blocker group compared with controls: 3·1 (95 per cent c.i. 1·9 to 4·7) versus 8·6 (7·6 to 9·8) per cent respectively (P < 0·001). Beta‐blocker therapy was the only modifiable protective factor identified in multivariable analysis of 30‐day all‐cause mortality (incidence rate ratio 0·31, 95 per cent c.i. 0·20 to 0·47; P < 0·001) and was associated with a significant reduction in death of cardiovascular, respiratory, sepsis and multiple organ failure origin.
Preoperative beta‐blocker therapy may be associated with a reduction in 30‐day mortality following emergency colonic cancer surgery.Full text
You may also be interested in
Authors: D. S. Keller, C. Reali, A. Spinelli, M. Penna, F. Di Candido, C. Cunningham et al.
Authors: C. F. Justiniano, Z. Xu, A. Z. Becerra, C. T. Aquina, C. I. Boodry, L. K. Temple et al.
Functional outcomes from a randomized trial of early closure of temporary ileostomy after rectal excision for cancer.
Authors: C. Keane, J. Park, S. Öberg, A. Wedin, D. Bock, G. O'Grady et al.
Authors: R. J. Meinds, A. F. W. van der Steeg, C. E. J. Sloots, M. J. Witvliet, I. de Blaauw, W. G. van Gemert et al.
Influence of the level of sacrectomy on survival in patients with locally advanced and recurrent rectal cancer.
Authors: Y. C. Lau, K. Jongerius, C. Wakeman, A. G. Heriot, M. J. Solomon, P. M. Sagar et al.
Cost‐effectiveness analysis of a multicentre randomized clinical trial comparing surgery with conservative management for recurrent and ongoing diverticulitis (DIRECT trial).
Authors: H. E. Bolkenstein, G. A. de Wit, E. C. J. Consten, B. J. M. Van de Wall, I. A. M. J. Broeders, W. A. Draaisma et al.
Notes: Maintained benefits
Authors: L. Koskenvuo, N. Malila, J. Pitkäniemi, J. Miettinen, S. Heikkinen, V. Sallinen et al.
Notes: Only of benefit in men.
Authors: I. van 't Sant, W. J. van Eden, M. P. Engbersen, N. F. M. Kok, K. Woensdregt, D. M. J. Lambregts et al.
Notes: Promising staging tool
Authors: C. T. Aquina, A. Z. Becerra, Z. Xu, C. F. Justiniano, K. Noyes, J. R. T. Monson et al.
Notes: Non‐operative management better
Cost‐effectiveness of liver transplantation in patients with colorectal metastases confined to the liver. BJS 2019; 106: 132-141.
Authors: G. M. W. Bjørnelv, S. Dueland, P.‐D. Line, P. Joranger, Å. A. Fretland, B. Edwin et al.
Notes: Not cost effective for everyone
Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer. BJS 2018; 105: 1553-1572.
Authors: R. Clifford, N. Govindarajah, J. L. Parsons, S. Gollins, N. P. West, D. Vimalachandran et al.
Notes: Promising agents coming
Bowel dysfunction after sigmoid resection for cancer and its impact on quality of life. BJS 2019; 106: 142-151.
Authors: H. Elfeki, H. M. Larsen, K. J. Emmertsen, P. Christensen, M. Youssef, W. Khafagy et al.
Notes: Substantial impairment common